A generic image of a pair of glasses on top of a calculator
Markets

Top-Rated Stocks: Zoetis Sees Composite Rating Climb To 97

A generic image of a pair of glasses on top of a calculator
Shutterstock photo

On Friday, Zoetis ( ZTS ) got an upgrade for its IBD SmartSelect Composite Rating from 91 to 97.

[ibd-display-video id=2385970 width=50 float=left autostart=true] The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher grade in the early stages of a new price run.

Zoetis is currently extended beyond a proper buy zone after breaking out from a 63.95 buy point in a flat base.

See How IBD Helps You Make More Money In Stocks

The stock earns a 96 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 96% of all stocks.

Its Accumulation/Distribution Rating of A- shows heavy buying by institutional investors over the last 13 weeks.

In Q4, the company posted 47% earnings growth. It has now posted accelerating EPS growth for two consecutive quarters. Top line growth climbed 14%, up from 9% in the prior report. The company has now posted rising growth in each of the last two reports.

Zoetis earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. AbbVie ( ABBV ) is the No. 1-ranked stock within the group.

RELATED:

Which Companies Are Now Outperforming 95% Of All Stocks?

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ZTS ABBV

Other Topics

Stocks

Latest Markets Videos